Linda West - Jul 1, 2022 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Role: Director
Signature: /s/ Christopher Degnan, Attorney-in-Fact for Linda West
Stock symbol: GRTX
Transactions as of: Jul 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/5/2022, 04:05 PM
Previous filing: Jun 16, 2022
Next filing: May 31, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GRTX	Stock Option (Right to Buy)	Award	$0	+58.5K		$0.00	58.5K	Jul 1, 2022	Common Stock	58.5K	$1.29	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date.

Content

This option was awarded pursuant to the "elective option" provisions of the Issuer's non-employee director compensation program for the Reporting Peron's service on the Issuer's Board and certain of its committees. This option shall vest and become exercisable as to 25% of the shares subject to the option upon the Reporting Person completing each three months of continuous service as a Non-Employee Director, or in the applicable committee position, following the date of grant, provided that the fourth and final tranche of the option will vest and become exercisable on the earlier of July 1, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director, or in the applicable committee position, through such vesting date.